TY - JOUR
T1 - Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides
AU - Fukunaga, Yasutomo
AU - Itoh, Hiroshi
AU - Doi, Kentaro
AU - Tanaka, Tokuji
AU - Yamashita, Jun
AU - Chun, Tae Hwa
AU - Inoue, Mayumi
AU - Masatsugu, Ken
AU - Sawada, Naoki
AU - Saito, Takatoshi
AU - Hosoda, Kiminori
AU - Kook, Hyun
AU - Ueda, Makiko
AU - Nakao, Kazuwa
N1 - Funding Information:
We thank A. Sone, A. Nonoguchi, and Y. Takada for their excellent secretarial work. This work was supported in part by research grants from the Japanese Ministry of Education, Science and Culture, the Japanese Ministry of Health and Welfare, ‘Research for the Future (RFTF)’ of Japan Society for the Promotion of Science (JSPS-RFTF 98 L00801, JSPS-RFTF 96 100204), and Smoking Research Foundation.
PY - 2001
Y1 - 2001
N2 - Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor γ (PPARγ), the crucial transcription factor for adipocytes. Recent studies showed that PPARγ is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARγ gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10-8 M) significantly stimulated 3H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10-5 M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.
AB - Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor γ (PPARγ), the crucial transcription factor for adipocytes. Recent studies showed that PPARγ is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARγ gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10-8 M) significantly stimulated 3H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10-5 M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.
KW - C-type natriuretic peptide
KW - Endothelial cells
KW - Endothelin
KW - Growth
KW - Insulin resistance
KW - Peroxisome proliferator-activated receptor
KW - Thiazolidinediones
UR - http://www.scopus.com/inward/record.url?scp=0034898803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034898803&partnerID=8YFLogxK
U2 - 10.1016/S0021-9150(01)00430-0
DO - 10.1016/S0021-9150(01)00430-0
M3 - Article
C2 - 11500181
AN - SCOPUS:0034898803
VL - 158
SP - 113
EP - 119
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 1
ER -